A carregar...
Patterns of practice with third-line anti-EGFR antibody for metastatic colorectal cancer
BACKGROUND: Therapy with anti-epidermal growth factor receptor (egfr) monoclonal antibody improves outcomes for patients with metastatic colorectal cancer (mcrc) in the first-, second-, and third-line trial settings. In British Columbia, the use of egfr inhibitors (egfris) is confined to third-line...
Na minha lista:
| Publicado no: | Curr Oncol |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Multimed Inc.
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5081009/ https://ncbi.nlm.nih.gov/pubmed/27803597 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.23.3030 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|